Core Viewpoint - Revelation Biosciences Inc. is set to present new clinical data on the therapeutic benefits of Gemini for treating acute kidney injury (AKI) and chronic kidney disease (CKD) at an upcoming conference, highlighting significant improvements in patient conditions [1] Group 1: Clinical Data Presentation - The presentation will include additional positive data from the recently completed PRIME Clinical Study [1] - The conference will take place at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego from March 29 to April 1, 2026 [1] - The data demonstrates normalization of the hyperinflammatory state in stage 3 and 4 CKD patients [1] Group 2: Therapeutic Benefits - The presented data indicates a restoration of immunocompetence in patients with CKD [1]

Core Insights - Revelation Biosciences, Inc. has commenced GMP manufacturing of GEMINI and placebo, which is essential for later stage clinical studies [1][2] - The CEO emphasized the importance of this manufacturing run in advancing the company's pipeline and expediting clinical programs [2] - The company recently met with the FDA to discuss the clinical development and regulatory approval pathway for GEMINI as a treatment for acute kidney injury (AKI) [3] Company Overview - Revelation Biosciences is a clinical-stage life sciences company focused on rebalancing inflammation through its proprietary formulation, GEMINI [7] - GEMINI is a toll-like receptor 4 (TLR4) agonist aimed at treating acute and chronic diseases related to dysregulated inflammation [4] - The company is evaluating GEMINI for multiple applications, including acute kidney injury, chronic kidney disease, severe burn-related hyperinflammation, and post-surgical infection prevention [4] Industry Context - Acute Kidney Injury (AKI) affects over 10% of hospitalized patients and more than 50% of ICU admissions, highlighting the need for new therapies [6] - AKI can lead to severe complications, including chronic kidney disease and increased mortality rates, underscoring the urgency for effective treatments [5][6]

Core Insights - Revelation Biosciences, Inc. has successfully submitted and received acceptance for the end-of-phase 1 meeting package to the FDA [1] - The company is on track to hold the meeting later this year, which aims to gather agency feedback on the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI) [1] Company Developments - The primary focus of the meeting with the FDA is to establish feedback regarding the clinical development of Gemini [1] - The company is positioned as a clinical-stage life sciences entity concentrating on rebalancing inflammation [1]

Core Insights - Revelation Biosciences, Inc. is focused on rebalancing inflammation and has made significant progress in its Phase 1b PRIME clinical study for stage 3 and 4 chronic kidney disease (CKD) patients [1] - The primary endpoint of the study, which evaluates the safety and tolerability of escalating doses of Gemini, has been successfully met [1] - The company is set to host a corporate update webcast/conference call to discuss the groundbreaking activity data from the clinical study [1] Company Overview - Revelation Biosciences, Inc. is a clinical-stage life sciences company [1] - The company aims to potentially revolutionize the treatment of acute and chronic inflammatory diseases through its innovative approach [1] Clinical Study Details - The Phase 1b PRIME clinical study focuses on patients with stage 3 and 4 CKD [1] - The study's results indicate a normalization of the inflammatory response at the cellular level in these patients [1]